Jump to content


  • Posts

  • Joined

  • Last visited

  • Days Won


admin last won the day on September 18 2014

admin had the most liked content!

About admin

Profile Information

  • Gender
    Not Telling

Recent Profile Visitors

1,719 profile views

admin's Achievements

  1. until
    Update on Nail Disorders Thursday 25 May 2017 Queens Hotel, Cheltenham About The Meeting We are delighted to invite you to the British Hair and Nail Society - Update of Nail Disorders taking place at the Queens Hotel, Cheltenham. This is the first meeting of its kind and we are very excite to welcome you to what promises to be a great programme in a fantastic location. Agenda 09.30 - 10.15 Paediatric Nail disorders - David de Berker (Bristol Royal Infirmary) 10:15 - 11:00 Nail Fungi - Rod Hay (Professor of Cutaneous Infection KCL) 11:00 - 11:15 Coffee 11:30 - 12:!5 Contact Dermatitis and Nails - Portia Goldsmith (Barts Health) 12:15 - 13:00 Inflammatory Nail Disorders - Anita Takwale (Gloucestershire Hospitals NHS Foundation Trust) 13:00 - 14:00 Lunch 14:00 - 14:45 Management of Nail Disorders - A podiatric perspective - Ivan Bristow (University of Southampton) 14:45 - 15:30 Nail Cancers - David De Berker (Bristol Royal Infirmary) 15:30 - 16:15 Nail Surgery - Anshoo Sahota (Whipps Cross Hospital) Presentations from the Event are below: OnychomycosisGloucsRJH PDF.pdf Ivan Bristow Podiatry.pdf
  2. admin

    Test Event 2

    This is Test Event 1 Description. This is Test Event 1 Description. This is Test Event 1 Description. This is Test Event 1 Description. This is Test Event 1 Description. This is Test Event 1 Description. This is Test Event 1 Description. This is Test Event 1 Description. This is Test Event 1 Description. This is Test Event 1 Description.
  3. admin

    Test Event 1

    This is Test Event 1 Description. This is Test Event 1 Description. This is Test Event 1 Description. This is Test Event 1 Description. This is Test Event 1 Description. This is Test Event 1 Description. This is Test Event 1 Description. This is Test Event 1 Description. This is Test Event 1 Description. This is Test Event 1 Description.
  4. Provisional Programme 9:30-10:30 AGM 10:30 – 12:00 Hair & Nail CPC – Submitted cases for discussion 12:00-13:00 Nail Surgery Pearls 13:00-14:00 Lunch 14:00-15:00 The FFA Debate – Open discussion on possible aetiology, treatments, future research 15:00 -15:15 How I manage Folliculitis De Calvans & Dissecting cellulits 15:15-15:30 How I manage the child who’s hair doesn’t grow 16:00 Tea 16:20 The new website launch – how to use the clinical forum and database 17:00 Meeting Close
  5. until
    Hair and Nail Meetings 9th World Congress of Hair Research Miami, Florida USA, 18-21 November 2015 (http://www.hair2015.org/) Institute of Trichologists Annual Meeting Monday 27th October 2014 London European Nail Society Annual Meeting 8th October to preceed EADV Autumn meeting Amsterdam 8-12 October 2014 NAHRS Meeting at AAD 73rd Annual Meeting 20th March 2015, San Francisco NAHRS Meeting at SID 74th Annual Meeting 8th May 2015, Atlanta NAHRS Symposium 8th June 2015 preceeding World Congress of Dermatology Vancouver, Canada 17th European Hair Research Society (EHRS) Meeting, Kiev Ukraine 2015 (http://ehrs.org/the-17th-meeting-of-the-european-hair-research-society-will-be-held-in-kiev-ukraine-2015/)
  6. European Nail Society Pre Congress meeting at the Academic Medical Center of the University of Amsterdam. Date: Wednesday, October 8th, 2014, 9.00 to 12.00 Venue: Academic Medical Center Coster Room, Ground floor Meibergdreef 9 1105 AZ Amsterdam Program: 8.30 - 9.00 Registration 9.00 - 9.05 Introduction 9.05 - 9.30 Michaela Starace: Dermoscopy of the nail in benign and malignant disease Division of Dermatology, Department of Experimental, Diagnostic and Speciality Medicine, University of Bologna, Bologna, Italy 9.30 - 9.55 Adam Rubin: Nail Unit Biopsy Techniques for Optimal Evaluation of Inflammatory Disorders Assistant Professor of Dermatology, University of Pennsylvania 9.55 - 10.20 Anna-Christa de Vries, RCT infliximab versus etanercept in nail psoriasis Department of Dermatology, Academic Medical Center, University of Amsterdam 10.20 - 10.35 Coffee 10.35 - 11.00 Imke Ferket: Fumarates for Nail Psoriasis Department of Dermatology, Erasmus Medical Center, Rotterdam 11.00 - 11.30 Leon Plusjé: Dermal grafts in nail surgery Rode Kruis Ziekenhuis, Beverwijk 11.30 - 12.00 Your puzzling nail case discussed by a forum of international experts 12.00 - 12.30 Lunch Registration: Registration is free. Please send the registration form register before September 1st to stafsecretariaat@derma.umcn.nl Accreditations: We will apply for accreditation by: Nederlandse Vereniging voor Dermatologie en Venereologie.
  7. Hair loss (alopecia) is a common problem that has been shown to have a significant impact on psychological well-being and quality of life, and can sometimes also signify an underlying medical problem. Treatment of hair loss disorders is often challenging due to a number of factors, including limited understanding of the natural history of the condition, poor disease definitions, lack of validated severity scales and generally poor quality of evidence for treatment. Only a limited number of hair loss disorders have good quality randomised controlled trial (RCT) evidence to guide treatment choices. Further, access to supportive therapies (e.g. psychological support, wig provision, etc) can vary across the country and evidence for the most effective use of these interventions is generally poor. With kind funding from Alopecia UK, the British Hair and Nail Society proposed a priority setting partnership to encompass all types of hair loss with an aim of focusing clinical hair research on areas that meant the most to people with hair loss and clinicians/healthcare professionals alike. Inspired by previous PSPs in the field of dermatology, we hope to draw the attention of potential research funders to the unmet need in this distressing and under-researched group of conditions. The challenge of our particular PSP is how to reach, and harvest questions from, individuals representing many different, and rare, hair loss conditions. Many sufferers do not know their specific diagnosis and possibly do not seek treatment or are not able to access secondary and tertiary care specialists to achieve this. We feel that by keeping the process as open as possible we can harness expertise and opinions from individuals who have previously felt that their concerns and research priorities may have gone unheard. The process is off to a flying start with the initial survey under revision after a successful pilot, with the aim of the survey going live in early September. The steering group is currently in the process of identifying and engaging potential partners who will help publicise the survey. The steering group consists of 12 members including Jennifer Chambers (Patient and Admin lead), Paul Farrant (Dermatologist), Matt Harries (Dermatologist), Nigel Hunt (Psychologist), Andrew Messenger (Dermatologist), Carole Michaelides (Trichologist), Karena Moore-Millar (Patient and researcher in wig technology), Rachael Robinson (General Practitioner with Special Interest in Dermatology), Julie Rodgers (Patient), Jackie Tomlison (Alopecia UK trustee, nurse and patient), Sheela Upadhyaya (JLA Adviser and chair), and me (Dermatologist).
  8. Are JAK inhibitors the future for management of Alopecia Areata? In a recent edition of Nature an exciting new approach to managing alopecia areata was discussed. The research team demonstrated the crucial role of a particular white blood cell, known as the cytotoxic CD 8 T lymphocyte, more specifically the CD8 NKG2D T Cell. In a mouse model it was demonstrated that this cell promotes the development of alopecia areata and leads to the autoimmune attack on the hair follicle. It is likely that the CD8 cells produce Interferon gamma which leads to collapse of the normal immune privilege that surrounds a healthy hair follicle. In turn another cytokine (chemical messenger) is produced, - interleukin 15. These chemical messengers exert their effect by various pathways and one of the crucial elements downstream is maintained by the Janus Kinase (JAK) family of proteins. Blocking the JAK pathway would therefore prevent inflammation that leads to hair loss. The researchers demonstrated that by blocking the JAK pathway in mice, using inhibitors already developed for other diseases they were able to cause the mice with alopecia to completely regrow their hair. A systemic form of the same drug has been tested on a few patients with advanced and longstanding alopecia and this has caused hair regrowth too. Any maybe most exciting of all, topical formulations of the same drugs were shown to work too, meaning it may be possible to treat humans with alopecia with a topical JAK inhibitor. Of course this is very early days and larger studies need to investigate both efficacy and potential side effects and whether the topical formulation will work as well as systemic drugs, but for the first time ever new knowledge of a disease process is being used to develop a specific targeted therapy for alopecia areata.
  • Create New...